ProMIS reaffirms Q1 2027 PRECISE-AD data timing, reports Q3 2026 results
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
SEC filing
1 story
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
SEC filing